Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy
- Conditions
- Castration-Resistant Prostate Cancer
- Interventions
- Drug: Placebo
- Registration Number
- NCT00974311
- Lead Sponsor
- Pfizer
- Brief Summary
This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 1199
- Progressive prostate cancer
- Medical or surgical castration with testosterone less than 50 ng/dl
- One or two prior chemotherapy regimens. At least one chemotherapy regimen must have contained docetaxel
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Adequate bone marrow, hepatic, and renal function
- Able to swallow the study drug and comply with study requirements
- Informed consent
- Metastases in the brain or active epidural disease
- Another malignancy within the previous 5 years
- Clinically significant cardiovascular disease
- Gastrointestinal disorder affecting absorption
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Enzalutamide Enzalutamide Formerly MDV3100 Placebo Placebo -
- Primary Outcome Measures
Name Time Method Overall Survival During study period (up to 101 months) Survival was defined as time from randomization to death due to any cause. The duration of overall survival was right-censored for participants who were lost to follow-up since randomization or not known to have died at the data analysis cut-off date (this included participants who were known to have died after the data analysis cut-off date).
- Secondary Outcome Measures
Name Time Method Radiographic Progression-free Survival During DB phase (up to 24 months) Radiographic progression-free survival was defined as time from randomization to the earliest objective evidence of radiographic progression or death due to any cause. Participants were assessed for objective disease progression at regularly scheduled visits. The consensus guidelines of the Prostate Cancer Clinical Trials Working Group 2 were taken into consideration for the determination of disease progression. Radiographic disease progression was defined by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 for soft tissue disease, or the appearance of two or more new bone lesions on bone scan. Progression at the first scheduled reassessment at Week 13 required a confirmatory scan 6 or more weeks later. Participants who did not reach the endpoint were right censored at their last assessment.
Time to First Skeletal-related Event During DB Phase (up to 24 months) The time to first skeletal-related event was defined as time from randomization to the occurrence of the first skeletal-related event. Participants were assessed for skeletal-related events at regularly scheduled visits. A skeletal-related event was defined as radiation therapy or surgery to bone, pathologic bone fracture, spinal cord compression, or change of antineoplastic therapy to treat bone pain. Participants who did not reach the endpoint were right censored at their last assessment.
Percentage of Participants Who Were Responders for Functional Assessment of Cancer Therapy-Prostate (FACT-P) Baseline up to 24 months The FACT-P was a 39-item participant questionnaire which assessed physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and additional prostate cancer specific concerns (12 items). All items were scored from 0 (not at all) to 4 (very much). The sum of scores on all 5 domains constitutes the global FACT-P. The global/total FACT-P score ranged from 0 (worst) to 156 (best), higher scores indicate better health status. Responders were those participants who had a 10-point improvement in their total FACT-P score, as compared with baseline, on two consecutive measurements obtained at least 3 weeks apart.
Time to Prostate-specific Antigen (PSA) Progression Baseline and at every study visit from Week 13 while on study drug (up to 24 months) Time to PSA progression was defined as time from randomization to PSA progression. Participants who did not reach the endpoint were right censored at their last assessment or for participants with no post-baseline PSA assessment, date of randomization. For participants with PSA declines at Week 13, the PSA progression date was defined as the date that a \>=25% increase and an absolute increase of \>=2 nanogram per milliliter (ng/mL) above the nadir was documented, which was confirmed by a second consecutive value obtained 3 or more weeks later (required only if PSA progression did not occur at last PSA assessment). For participants with no PSA declines at Week 13, PSA progression date was defined as the date that a \>=25% increase and an absolute increase of \>=2 ng/mL above the baseline was documented, which was confirmed by a second consecutive value 3 or more weeks later (required only if PSA progression did not occur at last PSA assessment).
Percentage of Participants With Pain Palliation Baseline up to 24 months The proportion of participants with pain palliation was assessed for participants with a stable and sufficient pain burden at study entry. Pain burden was measured by question #3 of the Brief Pain Inventory (Short Form). This scale measures pain on a 0 to 10 scale with 0 indicating no pain and 10 indicating pain as bad as you can imagine. Pain palliation at Week 13 was determined for the proportion of men with baseline bone metastasis(es) who had baseline pain attributable to the metastasis(es). Palliation was defined as \>=30% reduction in average pain score at Week 13 compared to baseline without a \>=30% increase in analgesic use.
Percentage of Participants With Prostate Specific Antigen (PSA) Response During DB phase (up to 24 months) Participants were evaluable for PSA response rate if they had a PSA level measured at baseline and at least 1 post-baseline assessment. Both PSA responses of \> 50% and \> 90% were determined. PSA responses required confirmation with a subsequent assessment that was conducted at least 3 weeks later.
Percentage of Participants With Soft-tissue Objective Response During DB phase (up to 24 months) The best overall soft tissue response as assessed using RECIST v1.1 during the study was summarized using the investigators' response assessments and also the derived response assessments by treatment group. Only participants with measurable soft tissue disease at screening were included in this analysis. Participants with measurable disease at screening are participants who had at least 1 target lesion identified per RECIST v1.1 at screening. Percentage of participants summarizes the number of participants with complete or partial objective response (%). Soft Tissue assessment based on Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
European Quality of Life Five-Domain (EQ-5D) Scale Week 13 EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility or index score. Five parameters (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) were assessed on 3-point categorical scale (1= no problems, 2= some/moderate problems and 3= severe problem). Score were transformed and resulted in a total EQ-5D score range of 0 (worst imaginable health state) to 100 (best imaginable health state), with higher scores indicating better health and quality of life.
Percentage of Participants With Circulating Tumor Cell (CTC) Conversion Baseline up to 24 months CTC conversion was assessed for participants with baseline CTC counts of greater than or equal to (\>=) 5 cells per 7.5 milliliter (mL) of blood. A CTC conversion was defined as a decline in the CTC count to less than (\<) 5 cells per 7.5 mL of blood. In this outcome measure percentage of participants with CTC conversion was reported.
Trial Locations
- Locations (220)
LAC & USC Medical Center
🇺🇸Los Angeles, California, United States
Ronald Reagan UCLA Medical Center
🇺🇸Los Angeles, California, United States
Hospital of the University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center
🇺🇸Philadelphia, Pennsylvania, United States
VA Pittsburgh Healthcare System
🇺🇸Pittsburgh, Pennsylvania, United States
Parkland Health and Hospital System
🇺🇸Dallas, Texas, United States
Princess Margaret Hospital
🇨🇦Toronto, Ontario, Canada
Sir Charles Gairdner Hospital, Department of Medical Oncology
🇦🇺Nedlands, Western Australia, Australia
Centre Hospitalier Lyon sud
🇫🇷Pierre Benite, France
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
🇮🇹Orbassano, TO, Italy
FacharztzentrumInnere Medizin
🇩🇪Berlin, Germany
Klinik fuer Urologie
🇩🇪Tuebingen, Germany
Medizinische Hochschule Hannover
🇩🇪Hannover, Germany
Azienda Ospedaliera San Camillo Forlanini
🇮🇹Rome, Italy
Charite - Universitaetsmedizin Berlin-Campus Benjamin Franklin
🇩🇪Berlin, Germany
Centre Rene Gauducheau
🇫🇷SAINT-HERBLAIN Cedex, France
Gemeinschaftspraxis Fuer Nuklearmedizin
🇩🇪Berlin, Germany
Centre Hospitalier
🇫🇷Saint Etienne Cedex 2, France
Radiologische Gemeinschaftspraxis
🇩🇪Berlin, Germany
Azienda Ospedaliero-Universitaria di Modena Policlinico
🇮🇹Via Del Pozzo 71, Modena, Italy
Wojewodzki szpital specjalistyczny im. Janusza Korczaka
🇵🇱Slupsk, Poland
Martini-Klinik am UKE GmbH
🇩🇪Hamburg, Germany
Hopital Foch
🇫🇷Suresnes Cedex, France
VU Medisch Centrum
🇳🇱Amsterdam, Netherlands
Belfast City Hospital
🇬🇧Belfast, United Kingdom
Bristol Royal Infirmary
🇬🇧Bristol, United Kingdom
Hospital del Mar
🇪🇸Barcelona, Spain
Sandton Oncology Centre
🇿🇦Sandton, South Africa
Praxis Dr. Wolfgang Hoelzer
🇩🇪Berlin, Germany
Radiodiagnostic Cetir Clinica Pilar
🇪🇸Barcelona, Spain
Hopelands Cancer Centre
🇿🇦Durban, South Africa
Universitaetsklinikum Muenster, Klinik fuer Klinische Radiologie
🇩🇪Muenster, Germany
Medizinische Hochschule Hannover - Klinik fuer Urologie und Urologische Onkologie
🇩🇪Hannover, Germany
UMC St. Radboud
🇳🇱Nijmegen, Netherlands
Erasmus MC
🇳🇱Rotterdam, Netherlands
Cambridge University Hospitals NHS Foundation Trust
🇬🇧Cambridge, United Kingdom
Institut de Cancerologie de la Loire
🇫🇷Saint Priest en Jarez, France
Centre d'Investigation Clinique, (CIE3)
🇫🇷Saint-Etienne CEDEX 2, France
Staedtisches Klinikum Braunschweig gGmbH
🇩🇪Braunschweig, Germany
Clinica Universidad de Navarra
🇪🇸Pamplona, Spain
Universitaetsklinikum Aachen
🇩🇪Aachen, Germany
Regionalny Szpital Specjalistyczny im. Dr. Wladyslawa Bieganskiego
🇵🇱Grudziadz, Poland
Azienda Ospedaliera "Istituti Ospitalieri" di Cremona
🇮🇹Cremona, Italy
The Beatson West of Scotland Cancer Centre
🇬🇧Glasgow, United Kingdom
Uniwersyteckie Centrum Kliniczne
🇵🇱Gdansk, Poland
GVI Oncology
🇿🇦Port Elizabeth, South Africa
Hospital Madrid Norte Sanchinarro
🇪🇸Madrid, Spain
Hospital Universitario Germans Trias i Pujol
🇪🇸Badalona, Spain
Hammersmith Hospital
🇬🇧London, United Kingdom
Bishops Wood Hospital
🇬🇧Northwood, Middlesex, United Kingdom
Hospital Santa Creu i Sant Pau
🇪🇸Barcelona, Spain
Hospital Vall d'Hebron
🇪🇸Barcelona, Spain
Mayo Clinic Hospital
🇺🇸Phoenix, Arizona, United States
University of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Pharmaceutical Research Services
🇺🇸Durham, North Carolina, United States
Karmanos Cancer Institute
🇺🇸Detroit, Michigan, United States
Comprehensive Cancer Centers of Nevada
🇺🇸Las Vegas, Nevada, United States
Portland VA Medical Center
🇺🇸Portland, Oregon, United States
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States
Mount Vernon Hospital
🇬🇧Northwood, Middlesex, United Kingdom
Cancer Centre
🇬🇧Birmingham, United Kingdom
Bristol Haematology & Oncology Centre
🇬🇧Bristol, United Kingdom
University College Hospital
🇬🇧London, United Kingdom
Northern Centre for Cancer Care
🇬🇧Newcastle upon Tyne, United Kingdom
Churchill Hospital
🇬🇧Oxford, United Kingdom
Hopital Europeen Georges Pompidou
🇫🇷Paris, France
Institut Paoli Calmettes
🇫🇷Marseille, France
Institut Gustave Roussy
🇫🇷Villejuif, France
Technical University Dresden
🇩🇪Dresden, Germany
Roentgenpraxis
🇩🇪Hamburg, Germany
Urologische Gemeinschaftspraxis Poppenbuettel
🇩🇪Hamburg, Germany
Universitaetsklinikum Heidelberg
🇩🇪Heidelberg, Germany
Universitaetsklinikum Muenster, Klinik und Poliklinik fuer Nuklearmedizin
🇩🇪Muenster, Germany
Universitaetsklinikum Muenster, Klinik und Poliklinik fuer Urologie
🇩🇪Muenster, Germany
Abt.f.Diagnostische u. Interventionelle Radiologie
🇩🇪Tuebingen, Germany
Nuklearmedizin
🇩🇪Tuebingen, Germany
Medical University of Vienna
🇦🇹Vienna, Austria
Icon Cancer Foundation
🇦🇺Milton, Queensland, Australia
Clinica Universitaria Privada Reina Fabiola
🇦🇷Cordoba, Provincia DE Cordoba, Argentina
Centro de Diagnostico Dr. Enrique Rossi
🇦🇷Ciudad Autonoma de Buenos Aires, Argentina
Premiere Oncology of Arizona
🇺🇸Scottsdale, Arizona, United States
USC Westside Prostate Cancer Center
🇺🇸Beverly Hills, California, United States
Cancer Center Oncology Medical Group
🇺🇸La Mesa, California, United States
Tower Cancer Research Foundation, Tower Hematology Oncology Medical Group
🇺🇸Beverly Hills, California, United States
City of Hope
🇺🇸Duarte, California, United States
UCLA
🇺🇸Los Angeles, California, United States
North County Oncology Medical Clinic, Inc,
🇺🇸Oceanside, California, United States
Medical Oncology Associates - SD
🇺🇸San Diego, California, United States
c/o Prostate Oncology Specialist, Inc.
🇺🇸Marina Del Rey, California, United States
Sharp Memorial Hospital Investigational Pharmacy
🇺🇸San Diego, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center
🇺🇸San Francisco, California, United States
City of Hope Medical Group
🇺🇸South Pasadena, California, United States
Sharp Rees-Stealy
🇺🇸San Diego, California, United States
Stanford Hospital and Clinics Research Pharmacy
🇺🇸Stanford, California, United States
C/O: Thomas Ferencz R.Ph., BCOP
🇺🇸New Haven, Connecticut, United States
Stanford University Medical Center
🇺🇸Stanford, California, United States
Research Pharmacist
🇺🇸Aurora, Colorado, United States
University of Colorado Denver, Anschutz Cancer Pavilion
🇺🇸Aurora, Colorado, United States
George Washington University-Medical Faculty Associates
🇺🇸Washington, District of Columbia, United States
Peachtree Hematology-Oncology Consultants, P.C.
🇺🇸Atlanta, Georgia, United States
Palm Beach Cancer Institute
🇺🇸West Palm Beach, Florida, United States
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
🇺🇸Baltimore, Maryland, United States
Massachusetts General Hospital (MGH)
🇺🇸Boston, Massachusetts, United States
University of Chicago
🇺🇸Chicago, Illinois, United States
University of Chicago Medical Center
🇺🇸Chicago, Illinois, United States
The Johns Hopkins Hospital
🇺🇸Baltimore, Maryland, United States
Brigham & Women's Hospital (BWH)
🇺🇸Boston, Massachusetts, United States
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Weisberg Cancer Treatment Center
🇺🇸Farmington Hills, Michigan, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Barnes-Jewish Hospital
🇺🇸Saint Louis, Missouri, United States
Washington University School of Medicine
🇺🇸Saint Louis, Missouri, United States
Siteman Cancer Center
🇺🇸Saint Peters, Missouri, United States
Roswell Park Cancer Institute
🇺🇸Buffalo, New York, United States
Nevada Cancer Institute, an affiliate of the UC San Diego Health System
🇺🇸Las Vegas, Nevada, United States
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
Memorial Sloan-Kettering Cancer Center
🇺🇸New York, New York, United States
Weill Cornell Medical College-New York Presbyterian Hospital
🇺🇸New York, New York, United States
UPMC Cancer Centers
🇺🇸Pittsburgh, Pennsylvania, United States
University of Pittsburgh Cancer Institute
🇺🇸Pittsburgh, Pennsylvania, United States
Carolina Urologic Research Center
🇺🇸Myrtle Beach, South Carolina, United States
Tennessee Oncology, PLLC
🇺🇸Smyrna, Tennessee, United States
Grand Strand Urology
🇺🇸Myrtle Beach, South Carolina, United States
The Sarah Cannon Research Institute
🇺🇸Nashville, Tennessee, United States
Virginia Oncology Associates
🇺🇸Williamsburg, Virginia, United States
Texas Oncology, Sammons Cancer Center
🇺🇸Dallas, Texas, United States
UT Southwestern Medical Center at Dallas
🇺🇸Dallas, Texas, United States
Virginia Cancer Institute
🇺🇸Richmond, Virginia, United States
Seattle Cancer Care Alliance
🇺🇸Seattle, Washington, United States
University of Wisconsin Hospital and Clinics
🇺🇸Madison, Wisconsin, United States
Instituto Oulton
🇦🇷Cordoba, Provincia DE Cordoba, Argentina
Instituto Medico de Asistencia e Investigaciones S.A (IMAI Research)
🇦🇷Buenos Aires, AR, Argentina
University of Washington Medical Center
🇺🇸Seattle, Washington, United States
Policlinico Neuquen
🇦🇷Neuquen, Provincia DE Neuquen, Argentina
Instituto de Investigaciones Clinicas Cipolletti
🇦🇷Cipolletti, Provincia DE RIO Negro, Argentina
Policlinico Modelo de Cipolletti
🇦🇷Cipolletti, Provincia DE RIO Negro, Argentina
Sanatorio Mapaci
🇦🇷Rosario, Provincia DE Santa FE, Argentina
Port Macquarie Base Hospital Pharmacy
🇦🇺Port Macquarie, New South Wales, Australia
Hospital Italiano Garibaldi
🇦🇷Rosario, Provincia DE Santa FE, Argentina
Instituto de Oncologia y Especialidades Medicas
🇦🇷Rosario, Provincia DE Santa FE, Argentina
Sydney Cancer Centre
🇦🇺Concord, New South Wales, Australia
Mid North Coast Diagnostic Imaging
🇦🇺Port Macquarie, New South Wales, Australia
North Coast Cancer Institute
🇦🇺Coffs Harbour, New South Wales, Australia
Port Macquarie Base Hospital
🇦🇺Port Macquarie, New South Wales, Australia
Prince of Wales Hospital, Department of Medical Oncology
🇦🇺Randwick, New South Wales, Australia
PRP Diagnostic Imaging
🇦🇺Wentworthville, New South Wales, Australia
Heart Care Partners
🇦🇺Auchenflower, Queensland, Australia
The Tweed Hospital
🇦🇺Tweed Heads, New South Wales, Australia
Sydney West Cancer Trials Centre, Department of Medical Oncology
🇦🇺Westmead, New South Wales, Australia
Icon Cancer Care Wesley
🇦🇺Auchenflower, Queensland, Australia
River City Pharmacy
🇦🇺Auchenflower, Queensland, Australia
Southern X-Ray Chermside
🇦🇺Chermside, Queensland, Australia
Cancer Care Services
🇦🇺Herston, Queensland, Australia
Icon Cancer Care Chermside
🇦🇺Chermside, Queensland, Australia
Icon Cancer Care South Brisbane
🇦🇺South Brisbane, Queensland, Australia
Mater Private Cardiology
🇦🇺South Brisbane, Queensland, Australia
Queensland X-Ray
🇦🇺South Brisbane, Queensland, Australia
Royal Hobart Hospital
🇦🇺Hobart, Tasmania, Australia
Department of Medical Oncology
🇦🇺Adelaide, South Australia, Australia
Peninsula Oncology Centre
🇦🇺Frankston, Victoria, Australia
Austin Hospital
🇦🇺Heidelberg, Victoria, Australia
60 Eleanor St
🇦🇺Footscray, Australia
Western Hospital
🇦🇺Footscray, Australia
The Royal Melbourne Hospital
🇦🇺Victoria, Australia
Krankenhaus der Barmherzigen Schwestern Linz
🇦🇹Linz, Austria
AZ Sint- Lucas
🇧🇪Ghent, Belgium
Cliniques Universitaires Saint- Luc
🇧🇪Brussels, Belgium
AZ Groeninge - Campus Kennedylaan
🇧🇪Kortrijk, Belgium
University Hospital Gasthuisberg
🇧🇪Leuven, Belgium
VZW Jessa Ziekenhuis
🇧🇪Hasselt, Belgium
Tom Baker Cancer Centre - Holy Cross Site
🇨🇦Calgary, Alberta, Canada
Cross Cancer Institute
🇨🇦Edmonton, Alberta, Canada
H.-Hartziekenhuis Roeselare-Menen vzw
🇧🇪Roeselare, Belgium
Tom Baker Cancer Centre
🇨🇦Calgary, Alberta, Canada
British Columbia Cancer Agency, Centre for the Southern Interior
🇨🇦Kelowna, British Columbia, Canada
Juravinski Cancer Centre
🇨🇦Hamilton, Ontario, Canada
British Columbia Cancer Agency - Vancouver Island Centre
🇨🇦Victoria, British Columbia, Canada
QEII Health Sciences Centre
🇨🇦Halifax, Nova Scotia, Canada
London Regional Cancer Program
🇨🇦London, Ontario, Canada
Centre Hospitalier de l'Universite de Montreal
🇨🇦Montreal, Quebec, Canada
The Urology Specialists.
🇨🇦Montreal, Quebec, Canada
Imagerie medicale de la Capitale
🇨🇦Quebec, Canada
CHU de Quebec
🇨🇦Quebec, Canada
Centre de rechereche clinique et evaluative en oncologie
🇨🇦Quebec, Canada
Centro Investigacion Clinica del Sur
🇨🇱Temuco, Chile
Hospital San Jose
🇨🇱Santiago, Chile
Centre hospitalier de Cannes
🇫🇷Cannes Cedex, France
Centre Paul Papin
🇫🇷Angers Cedex 9, France
Institut Bergonie
🇫🇷Bordeaux cedex, France
Centre Regional Francois Baclesse de lutte contre le cancer
🇫🇷Caen Cedex, France
CHU Henri Mondor
🇫🇷Creteil, France
Clinique Victor Hugo - Centre Jean Bernard
🇫🇷Le Mans, France
Centre Hospitalier Intercommunal Frejus-Saint Raphael
🇫🇷Frejus Cedex, France
Centre Leon Berard
🇫🇷Lyon Cedex 08, France
Centre hospitalier departemental Vendee
🇫🇷LA Roche sur Yon, France
Institut Curie
🇫🇷Paris, France
Groupement Hospitalier Edouard Herriot - Pavillon V
🇫🇷Lyon Cedex 3, France
CHU La Miletrie
🇫🇷Poitiers Cedex, France
Institut Jean Godinot
🇫🇷Reims Cedex, France
The Christie NHS Foundation Trust
🇬🇧Manchester, United Kingdom
The Manor Hospital Oxford
🇬🇧Oxford, United Kingdom
Mayo Clinic Arizona
🇺🇸Scottsdale, Arizona, United States
Beth Israel Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States
New Mexico Oncology Hematology Consultants, Ltd.
🇺🇸Albuquerque, New Mexico, United States
Universitaetsklinikum Mannheim
🇩🇪Mannheim, Germany
USC/Norris Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
Siteman Cancer Center-West County
🇺🇸Creve Coeur, Missouri, United States
Yale University School of Med
🇺🇸New Haven, Connecticut, United States
XRadiology
🇦🇺Toowong, Queensland, Australia
ISOTOPIX Ambulatorium fuer
🇦🇹Vienna, Austria
St. Vincent's Hospital Melbourne
🇦🇺Fitzroy, Victoria, Australia
Wojewodzki Szpital Specjalistyczny im. M. Kopernika
🇵🇱Lodz, Poland
AZ Groeninge - Campus Sint Maarten
🇧🇪Kortrijk, Belgium
The Royal Marsden Hospital
🇬🇧Sutton, Surrey, United Kingdom
Instituto Nacional del Cancer
🇨🇱Santiago, Chile
Instituto Oncologico
🇨🇱Vina del Mar, Chile
Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Regionalny Osrodek Onkologiczny
🇵🇱Lodz, Poland
Hollings Cancer Center
🇺🇸Charleston, South Carolina, United States
Medical University of South Carolina (MUSC)
🇺🇸Charleston, South Carolina, United States
B.C. Cancer Agency - Vancouver Centre
🇨🇦Vancouver, British Columbia, Canada